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Background: Antivirals are needed to combat the COVID-19 pandemic, which is caused by SARS-CoV-2. The
clinically-proven protease inhibitor Camostat mesylate inhibits SARS-CoV-2 infection by blocking the virus-
activating host cell protease TMPRSS2. However, antiviral activity of Camostat mesylate metabolites and
potential viral resistance have not been analyzed. Moreover, antiviral activity of Camostat mesylate in human
lung tissue remains to be demonstrated.
Methods: We used recombinant TMPRSS2, reporter particles bearing the spike protein of SARS-CoV-2 or
authentic SARS-CoV-2 to assess inhibition of TMPRSS2 and viral entry, respectively, by Camostat mesylate
and its metabolite GBPA.
Findings: We show that several TMPRSS2-related proteases activate SARS-CoV-2 and that two, TMPRSS11D
and TMPRSS13, are robustly expressed in the upper respiratory tract. However, entry mediated by these pro-
teases was blocked by Camostat mesylate. The Camostat metabolite GBPA inhibited recombinant TMPRSS2
with reduced efficiency as compared to Camostat mesylate. In contrast, both inhibitors exhibited similar anti-
viral activity and this correlated with the rapid conversion of Camostat mesylate into GBPA in the presence of
serum. Finally, Camostat mesylate and GBPA blocked SARS-CoV-2 spread in human lung tissue ex vivo and
the related protease inhibitor Nafamostat mesylate exerted augmented antiviral activity.
Interpretation: Our results suggest that SARS-CoV-2 can use TMPRSS2 and closely related proteases for spread
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The outbreak of the novel coronavirus severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in the city of Wuhan, China, in
the winter of 2019 and its subsequent pandemic spread has resulted
in more than 65 million cases of coronavirus disease 2019 and more
than 1.4 million deaths [1]. Antivirals designed to combat SARS-CoV-
2 are not available and repurposing of existing drugs developed
against other diseases is considered the fastest option to close this
gap [2]. Remdesivir, a drug generated to inhibit Ebola virus infection,
has recently been shown to reduce the duration of hospitalization for
COVID-19 [3]. However, the drug failed to reduce fatality significantly
[3] and beneficial effects were not observed in a previous clinical trial
[4], indicating that additional therapeutic options are needed.
We previously showed that the SARS-CoV-2 spike protein (S) uses
the host cell factors angiotensin-converting enzyme 2 (ACE2) and
transmembrane protease serine 2 (TMPRSS2) for entry into target
cells [5]. TMPRSS2 is a cellular type II transmembrane serine protease
(TTSP) expressed in human respiratory epithelium that cleaves and
thereby activates the viral S protein. Activation is essential for viral
infectivity and we found that the protease inhibitor Camostat mesy-
late, which is known to block TMPRSS2 activity [6], inhibits SARS-
CoV-2 infection of lung cells [5]. Camostat mesylate has been
approved for treatment of pancreatitis in Japan [79] and it is cur-
rently being investigated as a treatment of COVID-19 in several clini-
cal trials in Denmark, Israel and USA (NCT04321096, NCT04353284,
NCT04355052, NCT04374019).
The activity of TMPRSS2 is essential for SARS-CoV and MERS-CoV
lung infection and disease development [10,11]. Whether TMPRSS2-
independent pathways for S protein activation exist and contribute
to viral spread outside the lung is not fully understood. The S proteins
of SARS-CoV-2 and several other coronaviruses can be activated by
the pH-dependent endosomal cysteine protease cathepsin L in cer-
tain cell lines [5,1215]. However, this auxiliary S protein activation
pathway is not operative in the lung, likely due to low cathepsin L
expression [16]. Whether this pathway contributes to the recently
reported extrapulmonary spread of SARS-CoV-2 is unknown [17].
Similarly, it is unclear whether TTSPs other than TMPRSS2 can pro-
mote extrapulmonary SARS-CoV-2 spread. Finally, Camostat mesy-
late is rapidly hydrolyzed into the active metabolite 4-(4-
guanidinobenzoyloxy)phenylacetic acid (GBPA) in patients [1820]
but it is unknown to what extend GBPA inhibits TMPRSS2 activity.
Here, we identify TTSPs other than TMPRSS2 that can be used by
SARS-CoV-2 for S protein activation and demonstrate that they are
inhibited by Camostat mesylate. Moreover, we provide evidence that
Camostat mesylate is rapidly converted into GBPA in cell culture and
that GBPA inhibits SARS-CoV-2 entry with almost identical efficiency




BHK-21 (baby hamster kidney; ATCC no. CCL-10, RRID:
CVCL_1915), Vero E6 (African green Monkey kidney; ATCC no. CRL-
1586, RRID:CVCL_0574), Vero-TMPRSS2 (Vero cells that stablyibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
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DSMZ no. ACC 635, RRID:CVCL_0063)) cells were cultivated in Dul-
becco’s modified Eagle medium supplemented with 10% fetal bovine
serum (FCS, Biochrom), 100 U/mL of penicillin and 0.1 mg/mL of
streptomycin (PAN-Biotech). Vero-TMPRSS2 cells further received 1
mg/ml blasticidin (Invitrogen). Calu-3 cells (human lung adenocarci-
noma, RRID:CVCL_0609) were cultivated in minimum essential
medium (MEM) containing 10% FCS (Biochrom), 100 U/mL of penicil-
lin and 0.1 mg/mL of streptomycin (PAN-Biotech), 1x non-essential
amino acid solution (from 100x stock, PAA) and 1 mM sodium pyru-
vate (Thermo Fisher Scientific). Cell lines were incubated at 37 °C in a
humidified atmosphere containing 5% CO2. Transfection of 293T cells
was performed by calcium-phosphate precipitation, while Lipofect-
amine LTX with Plus reagent (Thermo Fisher Scientific) was used for
transfection of BHK-21 cells. Authentication of cell lines was per-
formed by STR-typing, amplification and sequencing of a fragment of
the cytochrome c oxidase gene, microscopical examination and/or
according to their growth characteristics. Further, cell lines were rou-
tinely tested for contamination by mycoplasma.
2.2. Plasmids
We employed pCAGGS-based expression vectors for VSV-G,
TMPRSS2, TMPRSS3, TMPRSS4, TMPRSS10, TMPRSS11A, TMPRSS11B,
TMPRSS11D, TMPRSS11E, TMPRSS11F and TMPRSS13 that have
either been previously described elsewhere or constructed based on
existing expression vectors [2126]. All proteases contained an N-
terminal cMYC-epitope tag. Further, we used pCG1-based expression
vectors for human ACE2 [27] and a SARS-2-S variant with a truncated
cytoplasmic tail for improved pseudotype particle production (dele-
tion of last 18 amino acid residues [28].
2.3. Preparation of Camostat mesylate and GBPA stocks
Camostat mesylate and GBPA were obtained from Ono pharmaceut-
icals Co., LTD. (Osaka/Japan) and reconstituted in DMSO to yield stock
solutions of 100mM. Stocks were stored at -20 °C, thawed immediately
before the experiment and residual compoundwas discarded.
2.4. Mass spectrometric quantification of Camostat mesylate
metabolization
Camostat mesylate was diluted to a concentration of ~15 mM in
either water or MEM containing 10% FCS and incubated for 1 min
(water and medium samples), 15 min, 30 min, 1 h, 2 h, 4 h, 8 h and
24 h (only medium samples) at 37 °C. Next, samples were snap-fro-
zen and stored at -80 °C until Camostat mesylate, GBPA (4-(4-guani-
dinobenzoyloxy) phenylacetic acid) and GBA (4-guanidinobenzoic
acid) levels were quantified by mass spectrometry. An ultra-high-
performance liquid chromatography tandem mass spectrometry
method using pneumatically assisted electrospray ionisation
(UHPLC-ESI-MS/MS) was used for quantification of Camostat and
GBPA in liquid samples. Calibrants based on blank sample were used
for the construction of 8-point calibration curves. Calibrants were
prepared with concentrations of 0.1, 1, 25, 50, 75, 100, 500 and
1000mg/L of Camostat and GBPA. In addition, a blank sample (a proc-
essed matrix sample without any added analyte) and a blank sample
spiked with SIL-IS were included to verify the absence of detectable
concentrations of the analytes. The calibration curves were created
by weighted (1/x) regression analysis of the SIL-IS normalised peak
areas (analyte area/IS area).
2.5. Preparation of pseudotype particles
We employed a previously published protocol to generate vesicu-
lar stomatitis virus (VSV) pseudotype particles that is based on aPlease cite this article as: M. Hoffmann et al., Camostat mesylate inh
metabolite GBPA exerts antiviral activity, EBioMedicine (2021), https://doreplication-deficient VSV containing eGFP and firefly luciferase (FLuc)
reporter genes, VSV*DG-FLuc (kindly provided by Gert Zimmer, Insti-
tute of Virology and Immunology IVI, Mittelh€ausern/Switzerland)
[5,29]. For this, HEK-293T cells were first transfected with expression
vector for either SARS-2-S or VSV-G (or empty expression vector,
control). At 24 h post transfection, cells were inoculated with VSV-G-
transcomplemented VSV*DG-FLuc at a multiplicity of infection (MOI)
of 3 and incubated for 1 h at 37 °C and 5% CO2. Next, the inoculum
was removed and cells were washed with PBS before fresh culture
mediumwas added. In case of cells transfected with SARS-2-S-encod-
ing vector or empty plasmid, the medium was spiked with anti-VSV-
G antibody (supernatant of CRL-2700 cells, 1:1,000, RRID:
CVCL_G654) in order to inactivate residual input virus containing
VSV-G. At 1618 h post inoculation, the culture supernatant was har-
vested and centrifuged (2,000 x g,|10 min) to remove cellular debris.
Clarified supernatants containing pseudotype particles were ali-
quoted and stored at -80 °C until further use.
2.6. Preparation of TMPRSS2 recombinant protein and substrate
Human TMPRSS2 (Recombinant N-terminus 6xHis, aa106-492)
(Cat # LS-G57269-20) protein was acquired from LifeSpan Bioscien-
ces. Peptide Boc-Gln-Ala-Arg-MCA for the enzyme substrate was
acquired from Peptide Institute, Inc.
2.7. TMPRSS2 enzyme assay
All different concentrations of test compounds were dissolved in
DMSO and diluted with assay buffer (50 mM Tris-HCl pH 8.0,
154 mM NaCl) to the final DMSO concentration of 1%. Compound
solution and Boc-Gln-Ala-Arg-MCA (10 mM final concentration) were
added into black 384-well black plates (Greiner Bio-One). Then, the
enzyme reaction was started by adding recombinant TMPRSS2 to a
final concentration of 2 mg/ml. Fluorescence intensity was recorded
using the Envision plate reader (PerkinElmer; excitation: 380 nm,
emission: 460 nm) in 2 min intervals over 60 min at room tempera-
ture (RT). The 50 % effective concentration (EC50) value was calcu-
lated based on the increasing rate of fluorescence intensity.
2.8. Molecular dynamics simulations and Markov modeling
We used extensive 50 ms all-atom molecular dynamics (MD) sim-
ulations of TMPRSS2 in complex with GBPA starting from a homology
model [30], in which drug binding and dissociation are sampled mul-
tiple times. We have re-evaluated the Markov model [31] presented
by Hempel and colleagues [32] to compare the dominant metastable
TMPRSS2 binding mode populations of GBPA (Fig. 5) to camostat. At
the simulated drug concentration, the association constant of GBPA is
found to have a maximum likelihood estimate of 60% compared to
that of Camostat mesylate, which, following the kinetic model
described by Hempel et al [32], results in a correspondingly lower
inhibitory activity. Bootstrapping of trajectories under the constraint
of comparable implied timescales yields a confidence interval of
51100% (68% percentile).
2.9. Transduction experiments
The day before transduction, BHK-21 cells were transfected with
an expression vector for ACE2 and either empty expression plasmid
(control) or expression vector encoding TMPRSS2, TMPRSS3,
TMPRSS4, TMPRSS10, TMPRSS11A, TMPRSS11B, TMPRSS11D,
TMPRSS11E, TMPRSS11F or TMPRSS13. For this, the old culture
medium was removed and 50 ml/well of fresh culture medium were
added. Next, transfection mixtures were prepared. For one well
0.1 mg of ACE2-encoding vector and 0.02 mg of protease-encoding
vector (or empty plasmid) were mixed with 0.2 ml of Plus reagent, 50ibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
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ofectamine LTX reagent. The transfection mix was vortexed and incu-
bated for 30 min at RT before it was added to the cells. At 6 h post
transfection, the transfection medium was replaced by fresh culture
medium and the cells were further incubated for ~18 h. Then, the
cells were either pre-incubated for 2 h with inhibitor (50 mM ammo-
nium chloride [Sigma-Aldrich], 100 mM Camostat mesylate or a com-
bination of both; cell treated with DMSO served as controls) before
transduction or directly inoculated with pseudotype particles bearing
SARS-2-S. For transduction of Calu-3 cells, cells were pre-incubated
for 2 h at 37 °C and 5% CO2 with different concentrations (0.01, 0.1, 1,
10, 100 mM) of Camostat mesylate, FOY-251 or DMSO (control),
before they were inoculated with pseudotype particles bearing SARS-
2-S or VSV-G. At 16 h post inoculation, transduction efficiency was
analyzed by measuring the activity of virus-encoded FLuc in cell
lysates. For this, the cell culture medium was removed and cells were
incubated for 30 min with 1x concentrated Cell Culture Lysis Reagent
(Promega), before cell lysates were transferred into white, opaque-
walled 96-well plates and luminescence was recorded (1 s/sample)
using a Hidex Sense plate luminometer (Hidex) and a commercial
substrate (Beetle-Juice, PJK).
2.10. Analysis of cell vitality
For the analysis of cell vitality of Calu-3 cells treated with Camo-
stat mesylate or FOY-251 the CellTiter-Glo Luminescent Cell Viability
Assay kit (Promega) was used. For this, Calu-3 cells were grown in
96-well plates to reach ~50% confluency, before they were incubated
in the presence of different concentrations of Camostat mesylate or
FOY-251 for 24 h. Cells treated with DMSO (solvent control) served
as controls. Following incubation, 100 ml of CellTiter-Glo substrate
were added per well and the samples were incubated for 30 min on a
rocking platform. In addition, fresh culture medium (without cells)
was also incubated with CellTiter-Glo substrate in order to define the
assay background. Following incubation, the samples were trans-
ferred into white, opaque-walled 96-well plates and luminescence
was recorded (200 m/sample) using a Hidex Sense plate luminometer
(Hidex).
2.11. Infection of Calu-3 cells with authentic SARS-CoV-2
The SARS-CoV-2 isolate hCoV-19/Germany/FI1103201/2020
(GISAID accession ID: EPI-ISL_463008) was isolated at the Institute of
Virology, Muenster, Germany, from a patient returning from the
Southern Tyrolean ski areas and propagated in Vero-TMPRSS2 cells.
Calu-3 cells were pre-incubated for 2 h with 2-fold concentrated
Camostat mesylate or FOY-251 (2, 20 or 200 mM), or DMSO (control),
before they were inoculated with SARS-CoV-2 at an MOI of 0.001 or
0.01. For this, the identical volume of virus-containing medium was
added to the inhibitor-containing medium on the cells (resulting in 1-
fold concentrated Camostat mesylate or FOY-251; 1, 10 or 100 mM).
Following 1 h of incubation at 37 °C and 5% CO2, the culture superna-
tant was removed and cells were washed two times with excess PBS
before culture medium containing 1-fold concentrated inhibitor was
added. Supernatants were harvested at 24 h post inoculation and sub-
jected to plaque titration. For this, confluent Vero-TMPRSS2 cells were
inoculated with 10-fold serial dilutions of supernatant and incubated
for 1 h 37 °C and 5% CO2. Thereafter, the inoculum was removed and
cells were incubated with culture medium containing 1% (w/v) methyl
cellulose. Plaques were counted at 48 h post infection and titers deter-
mined as plaque forming units per ml (pfu/ml).
2.12. SARS-CoV-2 infection of precision-cut lung slices
Precision-cut lung slices (PCLS) were prepared from lung tissue
acquired from patients who underwent lobe resection due to lungPlease cite this article as: M. Hoffmann et al., Camostat mesylate inh
metabolite GBPA exerts antiviral activity, EBioMedicine (2021), https://docancer at the Hannover Medical School (MHH, Hannover, Germany).
Only macroscopically disease-free parts of the lung were used for
experiments. Human lung slices with peripheral airways were pre-
pared as described before [33]. Briefly, a lung lobe was inflated with
2% agarose/DMEM/F12 solution. After the agarose polymerization,
the lung lobe was cut into slabs and tissue cores of 8 mm in diameter
were cut into 300 mm thin slices. PCLS were maintained in Hams F12
medium supplemented with 0.1 mg/ml streptomycin, 10 U/ml peni-
cillin, 0.05 mg/ml gentamicin and 0.01 mg/ml enrofloxacin. Prior to
infection, PCLS were placed in 48-well plates and checked for ciliary
activity by light microscopy. Only PCLS displaying a ciliary activity of
75% or higher were selected for the experiments. Next, PCLS were
pre-incubated for 2 h at 37 °C and 5% CO2 with Camostat mesylate,
FOY-251 or Nafamostat mesylate (0.5 mM or 5 mM) or received
medium containing DMSO (solvent control). Thereafter, the culture
supernatant was removed and PCLS were infected for 1 h at 37 °C
and 5% CO2 with SARS-CoV-2 isolate hCoV-19/Germany/FI1103201/
2020 (GISAID accession ID: EPI_ISL_463008)using an infectious dose
of 4 £ 105 pfu/ml (250 ml/well). Following infection, the inoculum
was removed and PCLS were washed three times with PBS before
500 ml culture medium containing the respective inhibitor or DMSO
was added. At 1 h (washing control) and 24 h (end point) post infec-
tion, 100 ml supernatant were collected and stored at -80 °C for virus
titration.
Virus titration was performed on Vero E6 cells (grown 12-well
plates), which were inoculated for 1 h at 37 °C and 5% CO2 with
850 ml of serial dilutions of the collected supernatants. Subsequently,
the inoculum was removed and cells were washed one time with
PBS, before they were overlaid with 1% plaque agarose (Biozym)-con-
taining Eagles minimal essential medium without phenol red (Lonza)
and further incubated. Plaques were counted at 72 h post infection
and titers determined as pfu/ml.
2.13. Analysis of TTSP expression in transfected cells by immunoblot
HEK-293T cells were grown in 12-wellplates and transfected with
expression vector coding for the respective TTSP (containing an N-
terminal cMYC-epitope tag) or empty expression vector. At 16 h post-
transfection, the culture medium was replenished and cells were fur-
ther incubated for 24 h at 37 °C and 5% CO2. Next, the culture
medium was removed, 150 ml of 2x SDS lysis buffer (5% glycerin, 1%
SDS, 2.5% ß-mercaptoethanol, 0.5% bromophenol blue, 0.5 mM EDTA,
0.5 M Tris; pH 6.8) were added per well and samples were incubated
for 10 min before they were transferred into 1.5 ml reaction tubes
and heated to 95 °C for 15 min. Subsequently, lysates were subjected
to SDS-PAGE (using 12.5% polyacrylamide gels) before proteins were
transferred onto nitrocellulose membrane (GE Healthcare) using the
Mini-PROTEAN Tetra Cell system (Bio-Rad). Following blocking of the
membranes in 5% milk solution (blotting-grade milk powder [Carl
Roth] dissolved in PBS containing 0.05% Tween-20 [AppliChem]; PBS-
T) for 1 h at RT, membranes were incubated over night at 4 °C in
either anti-cMYC antibody (clone 9E10)-containing hybridoma cell
supernatant (mouse, RRID:CVCL_G671; TTSP expression) or 5% milk
containing anti-ß-actin antibody (mouse, 1:1,000, Sigma-Aldrich,
RRID: AB_476744; loading control). Afterwards, the membranes
were washed three times with PBS-T before they were incubated
for 1 h at RT in 5% milk solution containing horseradish peroxi-
dase-coupled anti-mouse antibody (1:2,000, Dianova, RRID:
AB_10015289). Finally, membranes were washed three times
with PBS-T, incubated with an in house-prepared developing
solution (1 ml of solution A: 0.1 M Tris-HCl [pH 8.6], 250 mg/ml
luminol sodium salt; 100 ml of solution B: 1 mg/ml para-hydroxy-
coumaric acid dissolved in dimethyl sulfoxide [DMSO]; 1.5 ml of
0.3% H2O2 solution) and imaged using the ChemoCam imager
along with the ChemoStar Imager Software (version v.0.3.23;
Intas Science Imaging Instruments GmbH).ibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
i.org/10.1016/j.ebiom.2021.103255
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by single cell RNAseq
Bulk tissue expression data were obtained from the GTEx por-
tal [34]. The main site of lung specimen collection for the GTEx
project was the inferior segment of the left upper lobe, 1 cm
below the pleural surface. Single-cell expression data from human
lungs were obtained from GSE1229603. Only IPF and cryobiopsy
lung explants were used in this analysis. Single-cell expression
data from human airways was obtained from https://www.
genomique.eu/cellbrowser/HCA/4. The single-cell data was ana-
lyzed as described in Smith et al [35]. In short, dimensionality
reduction and clustering were performed on normalized expres-
sion data in python using Scanpy and the Multicore-TSNE pack-
age [36,37]. Low quality cells were filtered out by removing cells
with fewer than 500 detected genes. Highly variable genes were
computed using the Seurat approach in Scanpy, and then used to
calculate the principle component analysis. T-SNE and Leiden
clustering were calculated using nearest neighbors, with parame-
ters as described in the associated code. Cell clusters were labeled
manually by comparing the expression patterns of established
marker genes with the lists of differentially-expressed genes pro-
duced by Scanpy [3841]. The code used for performing these
analyses is available at https://github.com/joan-smith/covid19-pro
teases/.
2.15. Statistical analyses
All statistical analyses were performed using GraphPad Prism
(version 8.4.2, GraphPad Software, Inc.). Statistical significance of dif-
ferences between two datasets was analyzed by paired, two-tailed
student’s t-test while one- and two-way analysis of variance
(ANOVA) with Dunnett’s posttest was used for comparison of multi-
ple datasets (the exact method used is stated in the figure legends).
Effects were considered statistically significant when P values were
0.05 or lower. For the calculation of the turnover time required for
metabolization of 50% of Camostat mesylate (T1/2) as well as the EC50
values, which indicate the inhibitor concentration leading to 50%
reduction of transduction, non-linear fit regression models were
used.Fig. 1. Different type-II transmembrane serine proteases (TTSPs) can activate SARS-2-S in tr
tag were transiently expressed in 293T cells and expression analyzed by immunoblot with
results were obtained in three biological replicates. (b) BHK-21 cells transiently expressing
50 mM ammonium chloride or DMSO (control, indicated by dashed line) for 2 h, before they
SARS-2-S-driven cell entry of viral pseudotypes was analyzed by measuring the activity of v
efficiency in the absence of ammonium chloride was set as 100 % (indicated by dashed line).
formed with four technical replicates. Error bars indicate the standard error of the mean (S
nium chloride was analyzed by two-way analysis of variance (ANOVA) with Dunnett’s postte
0.0001; 0.0001; 0.0001).
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3. Results
3.1. Identification of novel SARS-CoV-2 S protein activating proteases
The TTSP family comprises several enzymes which have previ-
ously been shown to activate surface glycoproteins of coronaviruses
and other viruses, at least upon directed expression [22,24,26].
Therefore, we asked whether the S protein of SARS-CoV-2 (SARS-2-S)
can employ TTSPs other than TMPRSS2 for its activation. For this, we
first confirmed expression of the proteases by immunoblot using
antigenically tagged proteins. All proteases were expressed, although
at different levels, and for some more than one band was detected,
likely reflecting precursor (zymogen) and mature forms of the pro-
teases (Fig. 1a and Fig. S1). Next, we expressed different TTSPs along
with the SARS-CoV-2 receptor, ACE2, in the otherwise non-suscepti-
ble cell line BHK-21, treated the cells with ammonium chloride,
which blocks the cathepsin L-dependent, auxiliary activation path-
way, and transduced the cells with previously described vesicular
stomatitis virus (VSV)-based pseudotypes bearing SARS-2-S [5].
Ammonium chloride treatment strongly reduced SARS-2-S-driven
transduction and transduction was rescued upon expression ofansfected cells. (a) The indicated TTSPs equipped with an N-terminal C-MYC antigenic
anti-C-MYC antibody. Detection of ß-actin (ACTB) served as loading control. Similar
ACE2 and one of the indicated TTSPs (or empty vector) were pre-incubated with either
were inoculated with particles pseudotyped with SARS-2-S. At 16 h post inoculation,
irus-encoded luciferase activity in cell lysates. Data were further normalized and entry
Shown are the average (mean) data obtained from three biological replicates, each per-
EM). Statistical significance of differences in entry efficiency in the presence of ammo-
st (P values, from left to right: 0.0001; 0.9999; 0.0620; 0.9140; 0.4900; 0.0685; 0.0001;
ibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
i.org/10.1016/j.ebiom.2021.103255
ARTICLE IN PRESS
JID: EBIOM [m5G;March 3, 2021;22:42]
6 M. Hoffmann et al. / EBioMedicine 00 (2021) 103255TMPRSS2 (Fig. 1b), as expected. Notably, transduction was also effi-
ciently rescued by expression of TMPRSS13 and, to a lesser degree,
TMPRSS11D, TMPRSS11E and TMPRSS11F (Fig. 1b). Thus, SARS-2-S
can use diverse TTSPs for S protein activation upon overexpression,
with S protein activation by TMPRSS13 being particularly robust.
3.2. Several novel SARS-2-S activators are expressed in the airways and
throat
In order to obtain insights into whether SARS-2-S activating TTSPs
could contribute to viral spread in the infected host, we asked
whether these enzymes are expressed in viral target cells. For this,
we analyzed single-cell RNA-Seq datasets collected from human
lungs [42] and airways [43]. As previously reported [35,4448], ACE2
was expressed in the lung epithelial compartment, particularly
including alveolar type 2 cells, secretory (goblet/club) cells, and cili-
ated cells (Fig. 2a and Fig. S2). TMPRSS2 and TMPRSS13 were simi-
larly expressed across epithelial cells, although TMPRSS13 expression
was generally less robust. In contrast, expression of TMPRSS11-family
members was only rarely detected (Fig. 2a). We found that 53% of
ACE2+ cells in the lung co-express TMPRSS2, while 21% of ACE2+ cells
do not express TMPRSS2 but do express another TTSP capable of acti-
vating SARS-CoV-2 (Fig. S2). Within the airways, we observed ACE2
expression in secretory cells, ciliated cells, and suprabasal cells in
both the nasal turbinate and the trachea (Fig. 2b). Interestingly, the
expression pattern of the TTSPs in the airways was largely distinct:
TMPRSS2 was primarily expressed in ciliated and secretory cells,
TMPRSS11D was primarily expressed in basal cells, TMPRSS11E was
primarily expressed in ionocytes, and TMPRSS13 was primarily
expressed in nasal secretory cells (Fig. 2b). Within this dataset, 21% of
ACE2+ cells co-expressed TMPRSS2, while 24% of ACE2+ cells co-
expressed a different TTSP (Fig. S2). We note that in both the lungs
and the airways, TTSP expression is largely restricted to the epithelial
cell compartment, underscoring the fact that epithelial cells are the
primary cell population targeted by SARS-CoV-2 (Fig. S3). In total,
these results suggest that TMPRSS2 is the dominant SARS-CoV-2-acti-
vating protease in the lung, in keeping with findings made for SARS-
CoV and MERS-CoV, while the virus may use other activating pro-
teases for spread in the airways.
A recent study provided evidence for extrapulmonary replication of
SARS-CoV-2 in liver, colon, heart, kidney and blood in some patients
[17]. Therefore, we asked whether ACE2, TMPRSS2 and related SARS-
2-S-activating proteases are expressed in these organs, using pub-
lished resources [34,49]. Liver, colon, heart and kidney expressed
robust levels of ACE2 (Fig. 2c). Similarly, TMPRSS2 expression in colon,
liver and kidney was readily detectable, although expression levels
were lower than those measured for lung (Fig. 2c). In contrast, little to
no expression of TMPRSS11D, TMPRSS11E, TMPRSS11F and TMPRSS13
was detected in liver, colon, heart and kidney. Finally, TMPRSS13 was
expressed in lung and blood cells and expression of TMPRSS11-family
members was readily detectable in esophagus and salivary gland
(Fig. 2c). Collectively, the TTSPs able to activate SARS-2-S were not
expressed in appreciable levels in potential extrapulmonary targets of
SARS-CoV-2. The only exceptions were TMPRS13 and TMPRSS11-fam-
ily members that might contribute to SARS-CoV-2 infection of blood
cells and to viral spread in the throat, respectively.
3.3. Newly identified SARS-2-S activators are Camostat mesylate
sensitive
We next asked whether S protein activation by TTSP other than
TMPRSS2 can be inhibited by Camostat mesylate. To address this
question, we performed the rescue assay as described above but
investigated whether rescue can be blocked by Camostat mesylate. In
the absence of TTSP expression in target cells, ammonium chloride
but not Camostat mesylate reduced SARS-2-S-driven entry and thePlease cite this article as: M. Hoffmann et al., Camostat mesylate inh
metabolite GBPA exerts antiviral activity, EBioMedicine (2021), https://docombination of both substances resulted in similar inhibition as
observed upon ammonium chloride treatment alone (Fig. 3). These
results are in agreement with only the cathepsin L-dependent auxil-
iary pathway being operative in control BHK-21 cells, in agreement
with our published results [5]. In TMPRSS2 transfected cells ammo-
nium chloride did not efficiently block entry (Fig. 3), since under
those conditions TMPRSS2 is available for S protein activation. Simi-
larly, no entry inhibition was observed upon blockade of TMPRSS2
activity by Camostat mesylate (Fig. 3), since the cathepsin L-depen-
dent activation pathway remained operative. Finally, the combina-
tion of ammonium chloride and Camostat mesylate blocked entry
into these cells (Fig. 3), in keeping with both activation pathways
(cathepsin L and TMPRSS2) not being available under these condi-
tions. Importantly, a comparable inhibition pattern was observed for
all TTSPs able to activate SARS-2-S (Fig. 3), demonstrating that Camo-
stat mesylate will likely suppress SARS-CoV-2 activation by TMPRSS2
and TMPRSS2-related S protein activating serine proteases.
3.4. The Camostat mesylate metabolite GBPA shows reduced inhibition
of recombinant TMPRSS2
Multiple studies show that Camostat mesylate is rapidly con-
verted into its active metabolite, 4-(4-guanidinobenzoyloxy)phenyl-
acetic acid (GBPA) in animals and humans, followed by further
conversion of GBPA into the inactive metabolite 4-guanidinobenzoic
acid (GBA) [1820,50] (Fig. 6a). However, the capacity of GBPA to
inhibit the enzymatic activity of TMPRSS2 has not been examined. To
address this question, we compared inhibition of recombinant
TMPRSS2 by Camostat mesylate, GBPA and GBA. For this, we used
FOY-251, a methanesulfonate of GBPA, which is readily commercially
available. We found that FOY-251 exerted a 10-fold reduced capacity
to inhibit TMPRSS2 as compared to Camostat mesylate, although
both compounds completely suppressed TMPRSS2 activity at 1 mM
or higher (Fig. 4). In contrast, GBA was less active (Fig. 4). Thus, FOY-
251 blocks TMPRSS2 activity but with reduced efficiency as compared
to Camostat mesylate.
In order to obtain insights into the reduced inhibitory activity of
FOY-251, we investigated TMPRSS2 inhibition by GBPA on the molec-
ular level. For this, we used a combination of extensive all-atom
molecular dynamics (MD) simulations and Markov modeling of the
TMPRSS2-GBPA complex [32]. Guanidinobenzoate-containing drugs
such as Camostat mesylate and GBPA inhibit TMPRSS2 by first form-
ing a noncovalent precomplex which is then catalyzed to form a
long-lived covalent complex that is the main source of inhibition
[32]. However, the population of the short-lived precomplex directly
relates to the inhibitory activity [32]. By computing the TMPRSS2-
GBPA binding kinetics [32], we find that (i) the noncovalent
TMPRSS2-GBPA complex is metastable, rendering it suitable to form
a covalent inhibitory complex, and (ii) its population is 40% lower
compared to Camostat at equal drug concentrations, consistent with
the finding that FOY-251 is a viable but less potent inhibitor (Fig. 4).
Structurally, we find that GBPA binds in the same manner as Camo-
stat (Fig. 5, [32]). The main stabilizing interaction is its guanidinium
group binding into TMPRSS2’s S1 pocket, which is stabilized by a
transient salt bridge with Asp-435. The GBPA ester group can interact
with the catalytic Ser-441, making it prone for catalysis and forma-
tion of the catalytic complex. The slightly lower stability of the GBPA
compared to the Camostat mesylate-TMPRSS2 complex is consistent
with GBPA’s shorter tail, which has less possibilities to interact with
the hydrophobic patch on the TMPRSS2 binding site shown in Fig. 5,
left panel.
3.5. Rapid conversion of Camostat mesylate to GBPA in cell culture
Although Camostat mesylate is rapidly metabolized in animals
and humans, it is less clear whether conversion of Camostat mesylateibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
i.org/10.1016/j.ebiom.2021.103255
Fig. 2. SARS-2-S activating proteases are expressed in lung and blood. (a) T-SNE clustering of cells from the human lung [42]. Cells expressing the coronavirus receptor ACE2 are
highlighted in the right panel. These panels are reproduced with permission from Smith et al. [35]. Cells expressing various S-activating proteases in the human lung are highlighted.
(b) T-SNE clustering of cells from the human airway [43]. Cells expressing the coronavirus receptor ACE2 and the various S-activating proteases in the human airway are
highlighted. (c) Log2-normalized expression data of the indicated genes across different human tissues from the GTEx consortium [34]. Certain panels are reprinted from “Cigarette
Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract”, Developmental Cell 53, Joan C. Smith, Erin L. Saus-
ville, Vishruth Girish, Monet Lou Yuan, Anand Vasudevan, Kristen M. John, Jason M. Sheltzer, 514529, Copyright (2020), with permission from Elsevier.
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exposing Camostat mesylate to culture medium containing fetal calf
serum (FCS), which is standardly used for cell culture, followed byPlease cite this article as: M. Hoffmann et al., Camostat mesylate inh
metabolite GBPA exerts antiviral activity, EBioMedicine (2021), https://domass spectrometric quantification of Camostat mesylate and GBPA
levels. Camostat mesylate levels rapidly declined with a half-life of
approximately 2 h and the compound being barely detectable afteribits SARS-CoV-2 activation by TMPRSS2-related proteases and its
i.org/10.1016/j.ebiom.2021.103255
Fig. 3. Activation of SARS-2-S by TMPRSS2-related proteases can be suppressed by
Camostat mesylate. The experiment was performed as described for Fig. 1 with the
modifications that only TMPRSS2, TMPRSS11D, TMPRSS11E, TMPRSS11F and
TMPRSS13 were investigated and target cells were pre-treated with either 50 mM
ammonium chloride (red), 100 mM Camostat mesylate (blue) or a combination of both
(green). DMSO-treated cells served as controls. At 16 h post inoculation with viral par-
ticles bearing SARS-2-S, pseudotype entry was analyzed by measuring virus-encoded
luciferase activity in cell lysates. Data were further normalized and entry efficiency
into control-treated cells was set as 100%. Shown are the average (mean) data obtained
from three biological replicates, each performed with four technical replicates. Error
bars indicate the SEM. Statistical significance of differences in entry efficiency in
ammonium chloride-, Camostat mesylate- or ammonium chloride + Camostat mesy-
late-treated cells versus control-treated cells was analyzed by two-way ANOVA with
Dunnett’s posttest (P values, from left to right: NH4Cl [0.0001; 0.0001; 0.0001; 0.0001;
0.0001; 0.7334]; Camostat [0.9999; 0.8995; 0.9969; 0.9999; 0.9731; 0.9999]; NH4Cl/
Camostat [0.0001; 0.0001; 0.0001; 0.0001; 0.0001; 0.0001]).
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8 M. Hoffmann et al. / EBioMedicine 00 (2021) 1032558 h (Fig. 6b). Conversely, the levels of the Camostat mesylate metabo-
lite GBPA increased rapidly, with peak levels attained at 8 h, and then
remained relatively stable (Fig. 6b). Finally, the rapid metabolization
of Camostat mesylate into GBPA in the presence of serum was further
confirmed by incubation of Camostat mesylate in either water or
FCS-containing culture medium for 1 min followed by quantification
of Camostat mesylate and GBPA levels. While GBPA levels were at
background level when Camostat mesylate was incubated in water,
~5.4% of Camostat mesylate was metabolized into GBPA when incu-
bated in FCS-containing culture medium (Fig. 6c). Thus, CamostatFig. 4. Camostat mesylate and FOY-251 inhibit the activity of recombinant TMPRSS2.
Incubation of recombinant TMPRSS2 with the Boc-Gln-Ala-Arg-MCA peptide substrate
leads to the cleavage of the substrate and the release of the AMC(7-Amino-4-methyl-
coumarin) fluorophore, resulting in a fluorescent signal. Data were normalized against
the fluorescence signals obtained in the absence of test compounds (Camostat mesy-
late, FOY-251, GBA). The concentration-response data for each test compound were
plotted and modeled by a four-parameter logistic fit to determine the 50% effective
concentration (EC50) value. Inhibitory activity of Camostat mesylate (blue), FOY-251
(light blue) and GBA (red) against TMPRSS2 recombinant protein were visualized and
curve fitting was performed using GraphPad Prism. The average of two biological repli-
cates, each performed with four (Camostat mesylate and FOY-251) or two technical
replicates (GBA) is shown. EC50 values were 4 nM (Camostat mesylate), 70 nM (FOY-
251), >10mM (GBA).
Please cite this article as: M. Hoffmann et al., Camostat mesylate inh
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conditions, but the conversion is slower than what is observed in
humans [20].
3.6. Camostat mesylate and FOY-251 inhibit SARS-CoV-2 infection with
comparable efficiency
We finally compared the antiviral activity of Camostat mesylate
and FOY-251, the methanesulfonate of GBPA, in cell culture. The
reduced ability of FOY-251 to block the enzymatic activity of recom-
binant TMPRSS2 as compared to Camostat mesylate would suggest
that the compound should also exert reduced antiviral activity. On
the other hand, analysis of antiviral activity encompasses preincuba-
tion of target cells with Camostat mesylate for 2 h in the presence of
FCS, which allows conversion of Camostat mesylate into GBPA, as
demonstrated above. Indeed, titration experiments with VSV pseudo-
types and Calu-3 lung cells as targets revealed that entry inhibition
by FOY-251 was only slightly reduced as compared to Camostat
mesylate, with EC50 values of 107 nM (Camostat mesylate) and
178 nM (FOY-251) (Fig. 7). Moreover, no marked differences in inhi-
bition of infection of Calu-3 cells with authentic SARS-CoV-2 were
observed (Fig. 8a). Finally, both Camostat mesylate and FOY-251, as
well as another promising serine protease inhibitor for treatment of
SARS-CoV-2 infections, Nafamostat mesylate, inhibited SARS-CoV-2
infection of human precision-cut-lung slices (PCLS) ex vivo, and again
no major differences in inhibition efficiency were observed between
Camostat mesylate and FOY-251 (Fig. 8B). Thus, under the conditions
chosen Camostat mesylate and GBPA exerted roughly comparable
antiviral activity, likely due to conversion of Camostat mesylate into
GBPA.
4. Discussion
With the exception of Remdesivir, which reduces disease duration
(3), and dexamethasone, which reduces mortality in intensive care
unit (ICU) patients by targeting inflammation [51], there are currently
no drugs against COVID-19 with efficacy proven in clinical trials. We
previously reported that the protease inhibitor Camostat mesylate
inhibits SARS-CoV-2 infection of cultured lung cells by blocking the
virus-activating cellular protease TMPRSS2 [5]. Camostat mesylate
has been approved for human use in Japan and may thus constitute a
COVID-19 treatment option [52]. Here, we provide evidence that the
virus can use TMPRSS2-related proteases for S protein activation and
that these enzymes are also blocked by Camostat mesylate. More-
over, we demonstrate that the Camostat mesylate metabolite GBPA
exhibits reduced ability to block enzymatic activity of purified,
recombinant TMPRSS2 and is rapidly produced under cell culture
conditions. The rapid conversion of Camostat mesylate into GBPA
likely accounts for our finding that both compounds exerted similar
antiviral activity.
Knock-out of TMPRSS2 in mice markedly reduces SARS-CoV and
MERS-CoV infection [10] and disease development, and similar find-
ings have been reported for influenza A viruses (IAV) [5355], which
also use TMPRSS2 for glycoprotein activation [56]. Thus, TMPRSS2
activity is essential for CoV and IAV infection of the lung. In contrast,
several members of the TTSP family other than TMPRSS2 can activate
CoV and IAV glycoproteins and support viral spread in cell culture, at
least upon directed expression [24,26,56]. Whether these TTSPs play
a role in viral spread in the host is incompletely understood. For IAV,
infection by H3N2 viruses was found not to be fully TMPRSS2 depen-
dent [53,57] and an auxiliary role of TMPRSS4 in spread and patho-
genesis of H3N2 viruses has been reported [58,59]. Moreover,
influenza B viruses can use a broad range of TTSPs in cell culture
[59,60] and a prominent role of TMPRSS2 in viral spread in type II
pneumocytes has been reported [61] but viral spread in mice is
TMPRSS2 independent [59,62].ibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
i.org/10.1016/j.ebiom.2021.103255
Fig. 5. TMPRSS2 protease domain and GBPA interaction. A TMPRSS2 structure model is shown in the left panel, the active site is highlighted in cyan and catalytic triad residues are
shown in black. The representative structure of GBPA bound to TMPRSS2 in a reactive complex is shown in the right panel. The GBPA guanidinium head forms a salt bridge with
Asp-435 inside the S1 pocket. This transient complex, which is similar for Camostat, is prone to be catalyzed at the ester bond interacting with Ser-441, leading to a covalent com-
plex with TMPRSS2 inhibited.
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other than TMPRSS2 for S protein activation. Whether the TTSPs
found here to activate SARS-2-S upon directed expression play a role
in viral spread in the host remains to be investigated. Expression
analyses suggest that they may. TMPRSS13 activated SARS-2-S with
similar efficiency as TMPRSS2 and TMPRSS13 mRNA was found to be
coexpressed with ACE2 in type II pneumocytes, goblet and club cells
and basal cells. Moreover, TMPRSS13 was expressed in blood cells,
which may constitute a target for SARS-CoV-2 infection in some
patients. Finally, and most notably, SARS-2-S activating TTSPs
showed distinct expression patterns in the upper respiratory tract
and several potential target cells coexpressed ACE2 jointly with a
novel S protein activating TTSP but not TMPRSS2. Although viral
spread supported by TMPRSS13 and potentially other SARS-2-SFig. 6. Camostat mesylate is rapidly converted into GBPA in the presence of cell culture medi
GBPA and GBA in culture medium containing FCS. Camostat mesylate was added to FCS-con
tion for 1, 15, 30, 60, 120, 240, 480, and 1,440 min at 37 °C, snap-frozen and stored at -80 °C
Camostat mesylate and its metabolites GBPA (active) and GBA (inactive). Presented are the
ples). Error bars indicate the SEM. The turnover time that is required to cause metabolizatio
model and was determined to be 141.3 min (95% confidence interval = 116.5 to 171.7 min).
mesylate in either water or FCS-containing culture medium. For normalization, the combine
the compounds were calculated. Presented are the average (mean) data from three biologic
significance of differences in GBPA levels following incubation of Camostat mesylate in eithe
t-test (P = 0.0090). Abbreviations: FOY-51/GBPA = 4-(4-guanidinobenzoyloxy)phenylacetic ac
Please cite this article as: M. Hoffmann et al., Camostat mesylate inh
metabolite GBPA exerts antiviral activity, EBioMedicine (2021), https://doactivating TTSPs could contribute to transmission and pathogenesis,
it would still be sensitive to blockade by Camostat mesylate. Thus,
usage of auxiliary TTSPs for S protein activation would not confer
Camostat mesylate resistance to SARS-CoV-2.
In animals and humans Camostat mesylate is rapidly hydrolyzed
into the active metabolite 4-(4-guanidinobenzoyloxy) phenylacetic
acid (GBPA), which is further hydrolyzed to 4-guanidinobenzoic acid
(GBA) [1820]. GBPA was known to retain protease inhibitor activity
[50,63] but it was unclear whether GBPA would block TMPRSS2 activ-
ity with the same efficiency as Camostat mesylate. Inhibition studies
carried out with recombinant TMPRSS2 demonstrated that although
FOY-251 robustly blocked TMPRSS2 activity, the compound was
about 10-fold less active than Camostat mesylate, which roughly
matches results reported for other proteases [64]. This finding raisedum. (a) Metabolization of Camostat mesylate. (b) LC-MS/MS determination of Camostat,
taining culture medium at a concentration of 15 mM. Samples were taken after incuba-
. Samples were analyzed by LC-MS/MS and quantified regarding their content of intact
average (mean) data from three biological replicates (each performed with single sam-
n of 50 % of Camostat mesylate (T1/2) was further calculated by a non-linear regression
(c) Relative levels of Camostat mesylate and GBPA after incubation of 15 mM Camostat
d values of Camostat mesylate and GBPA were set as 100% and the relative fractions of
al replicates (each performed with single samples). Error bars indicate SEM. Statistical
r water or FCS-containing culture medium was analyzed by paired, two-tailed student’s
id; GBA = 4-guanidinobenzoic acid.
ibits SARS-CoV-2 activation by TMPRSS2-related proteases and its
i.org/10.1016/j.ebiom.2021.103255
Fig. 7. Camostat mesylate and FOY-251 inhibit SARS-2-S-driven cell entry with comparable efficiency. Calu-3 cells were pre-incubated with different concentrations of Camostat
mesylate (left panel), FOY-251 (right panel) or DMSO (control, indicated by dashed lines) for 2 h, before being inoculated with pseudotype particles bearing VSV-G (red) or SARS-2-
S (blue). Alternatively, in order to analyze potential negative effects of Camostat mesylate and FOY-251 on cell vitality (grey bars), cells received medium instead of pseudotype par-
ticles and were further incubated. At 16 h post inoculation, pseudotype entry and cell vitality were analyzed by measuring the activity of virus-encoded luciferase in cell lysates or
intracellular adenosine triphosphate levels (CellTiter-Glo assay), respectively. Data were further normalized and entry efficiency/cell vitality in the absence of Camostat mesylate
and FOY-251 was set as 100%. Shown are the average (mean) data obtained from three biological replicates, each performed with four technical replicates. Error bars indicate SEM.
Statistical significance of differences in entry efficiency/cell vitality in Camostat mesylate - or FOY-251-treated cells versus control-treated cells was analyzed by two-way ANOVA
with Dunnett’s posttest (P values, from left to right: Camostat/VSV-G [0.9999; 0.9999; 0.9996; 0.9733; 0.9986]; Camostat/SARS-2-S [0.0001; 0.0001; 0.0001; 0.0001; 0.0001]; Camo-
stat/Cell vitality [0.9999; 0.9999; 0.9999; 0.9998; 0.9810]; FOY-251/VSV-G [0.9997; 0.9730; 0.8867; 0.8838; 0.0326]; FOY-251/SARS-2-S [0.0001; 0.0001; 0.0001; 0.0001; 0.0001];
FOY-251/Cell vitality [0.9986; 0.9765; 0.9455; 0.9460; 0.9612]).
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occurs in cell culture systems used to assess antiviral activity of
Camostat mesylate. Indeed, Camostat mesylate was rapidly con-
verted into GBPA in the presence of fetal calf serum similar to find-
ings with human plasma [20]. The rapid Camostat mesylate
metabolization may account for Camostat mesylate and FOY-251
exerting roughly comparable antiviral activity when cells were
preincubated with these compounds for 2 h in the presence of
serum. However, providing formal proof for this hypothesis will
be challenging since the half-life of Camostat mesylate in human
plasma is less than 1 min [20]. Nevertheless, the EC50 measured
for FOY-251, 0.178 mM, has important implications for COVID-19
treatment, considering that continuous IV infusion of Camostat
mesylate (40 mg) resulted in a maximal plasma GBPAFig. 8. Camostat mesylate and FOY-251 inhibit SARS-CoV-2 infection with comparable effici
mesylate or FOY-251 as indicated. DMSO-treated cells served as control. Thereafter, cells w
cells were washed with PBS, before culture medium containing inhibitor or DMSO was added
plaque formation assay. Viral titers were determined as plaque forming units per ml (pfu/ml
and the results were confirmed in a separate experiment with another SARS-CoV-2 isolate. E
donors were pre-treated with 0.5 or 5 mM Camostat mesylate, FOY-251 or Nafamostat mes
After 1 h of incubation, the inoculum was removed and PCLS were washed with PBS, befo
supernatants were harvested at 24 h post infection and subjected to standard plaque forma
four (donor 1) or three (donor 2-4) technical replicates. Error bars indicate the SEM. One-wa
right: 0.5mM Camostat [0.1551]; 0.5mM FOY-251 [0.9919]; 0.5mMNafamostat [0.0006]; 5m
Please cite this article as: M. Hoffmann et al., Camostat mesylate inh
metabolite GBPA exerts antiviral activity, EBioMedicine (2021), https://doconcentration of 0.22 mM and peak plasma concentrations of
GBPA in humans upon oral intake of 200 mg Camostat mesylate
can reach 0.25 mM (http://www.shijiebiaopin.net/upload/prod
uct/201272318373223.PDF). Provided that concentrations in
plasma and in respiratory epithelium are comparable, this would
suggest that GBPA peak levels attained with the dosage approved
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